Arecor Therapeutics

Arecor is a revenue-generating clinical-stage drug developer. Its proprietary Arestat formulation platforms are the basis of an in-house and partnered pipeline of enhanced products with lower development risks and less onerous regulatory approvals.

View More

Specialty Hospital products formulation collaboration

Arecor Therapeutics | Lighthouse | 10 November 2022

View More

AT247 Phase I pump data confirms promising profile

Arecor Therapeutics | Lighthouse | 11 October 2022

View More

Broadening opportunities and preparing for the future

Arecor Therapeutics | Update | 21 September 2022

View More

Key clinical diabetes events on track for H222

Arecor Therapeutics | Lighthouse | 8 September 2022

View More

Acquisition of Tetris Pharma and £6m equity raise

Arecor Therapeutics | Lighthouse | 01 August 2022

View More

AT278 hits the sweet spot

Arecor Therapeutics | Update | 31 May 2022

View More

Ambitious, focussed, and delivering on its promise

Arecor Therapeutics | Update | 25 April 2022

View More

Formulation expertise exemplified in diabetes

Arecor Therapeutics | Update | 20 January 2021

View More

H121 results underline quality of management execution

Arecor Therapeutics | Lighthouse | 23 September 2021

View More
1 2